Geninus Selected for National New Drug Development Project with Anti-Cancer Vaccine Platform 'Vaccineus'

Geninus, a genome analysis specialist company (CEO Park Woong-yang), announced on the 5th that its anticancer vaccine platform under development, 'Vacinus,' has been selected as a supported project for the 3rd National New Drug Development Project in 2023, hosted by the Korea Drug Development Fund (KDDF).

With this project selection, Geninus will receive research funding from KDDF for two years to support the personalized anticancer vaccine pipeline 'VCN-100.'

Geninus's Vacinus is an anticancer vaccine platform created by combining the company's single-cell analysis technology with bioinformatics (BI) algorithms. The BI algorithm independently developed by Geninus, called 'VacPipe,' models neoantigens based on the patient's cancer genome data and immune cell single-cell analysis data. When these uniquely derived neoantigens are administered to the patient’s body, immune cells are activated, triggering an anticancer immune response.

Park Woong-yang, CEO of Geninus, explained, “Geninus's Vacinus platform demonstrates competitive efficacy in the personalized anticancer vaccine field led by global companies such as Moderna and BioNTech. This is the result of Geninus proudly being the first to incorporate single-cell analysis into the development process.”

Meanwhile, Geninus is conducting preclinical efficacy tests of the anticancer vaccine derived through Vacinus and plans to submit an IND (Investigational New Drug application) for phase 1 clinical trials of the personalized anticancer vaccine to the Ministry of Food and Drug Safety next year.